Indoco Remedies share price falls nearly 7% despite tender win in Germany
The share is trading 4.45 percent below its 52-week high and 104.58 percent above its 52-week low.08-12-2020
08-12-2020
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
INDOCO WINSMAJOR TENDERS IN GERMANY FOR ALLOPURINOL TABLETS08-12-2020
Indoco Remedies share price hits 52-week high after Dovetail India Fund buys 5 lakh shares
Dovetail India Fund purchased 5 lakh equity shares resulting in 0.58 percent stake at Rs 265.31 per share, data available on BSE showed. However, OHM Juniper Longterm Fund offloaded 0.54 percent stake in the company at a share price of Rs 265.31 per share.03-12-2020
Buy Indoco Remedies; target of Rs 352: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Indoco Remedies has recommended buy rating on the stock with a target price of Rs 352 in its research report dated November 09, 2020.12-11-2020
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Newspaper Publication
PUBLICATION OF QUARTER AND HALF YEAR ENDED RESULTS 30.09.202007-11-2020
INDOCO REMEDIES LTD. - 532612 - Regulation 23(9)
Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (LODR) Regulations, 2015 (Listing Regulations)06-11-2020
INDOCO REMEDIES LTD. - 532612 - Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2020
Standalone & Consolidated unaudited financial results for the quarter and half year ended 30.09.202006-11-2020
Indoco Remedies Ltd - 532612 - Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Schedule of Con Call Meeting22-10-2020
Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Publication of Board Meeting Notice20-10-2020
INDOCO REMEDIES LTD. - 532612 - Board Meeting Intimation for Unaudited Financial Results For The Quarter/Half Year Ended 30.09.2020
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2020 ,inter alia, to consider and approve Unaudited Financial results for the quarter/half year ended 30.09.202019-10-2020